Christopher Michael A MA

Show results for

Genomics (75)
Unknown (37)
Proteomics (18)
Transcriptomics (15)
Genomic (6)
Metabolomics (3)

Organisms

Homo sapiens (85)
Mus musculus (6)
Saccharomyces cerevisiae (2)
Xenopus laevis (1)

Repository

EGA (73)
biostudies-arrayexpress (18)
MassIVE (15)
dbGaP (6)
MetaboLights (3)
pride (2)
jPOST (1)

Tissue

Muscle cell (1)
Skeletal muscle (1)

Technology Type

Illumina 15K (8)
Mass spectrometry (3)
Mass Spectrometry (2)
Shotgun proteomics (2)
Affymetrix 6.0, Illumina_670k - Illuminus, Illumina 1.2M (1)
Illumina 610K Quad, Illumina 1.2M (1)
Illumina HiSeq 2000, ILLUMINA, Illumina HiSeq 2500 (1)
Illumina HiSeq 2500 (1)
Illumina_670k - Illuminus, Affymetrix 6.0, Illumina 1.2M (1)

Instrument Platform

SepSolve GCxGC-BenchTOF (4)
Q Exactive (3)
Agilent GC-qTOF (2)
Orbitrap Exploris 480 (2)
Illumina HiSeq 2500 (1)
Illumina NovaSeq 6000 (1)
Illumina HiSeq 4000 (1)
GCqTOF Agilent (1)
Orbitrap Fusion Lumos (1)
Pegasus 4D (1)
Flow injection analysis MS - negative (1)
Flow injection analysis MS - positive (1)
Liquid Chromatography MS - negative - reverse phase (1)
Liquid Chromatography MS - positive - reverse phase (1)
Xevo G2 QTOF (Waters) (1)

Publication Date

2025 (8)
2022 (3)
2020 (3)
2013 (3)
2012 (3)
2011 (3)
2010 (3)
2024 (3)
2015 (2)
2023 (2)
2019 (2)
2018 (2)
2016 (1)
2007 (1)

CHEBI ID

CHEBI:15318 (2)
CHEBI:15354 (2)
CHEBI:15971 (2)
CHEBI:16015 (2)
CHEBI:16411 (2)
CHEBI:16414 (2)
CHEBI:16467 (2)
CHEBI:16543 (2)
CHEBI:16704 (2)
CHEBI:16709 (2)
CHEBI:16750 (2)
CHEBI:16919 (2)
CHEBI:16924 (2)
CHEBI:17154 (2)
CHEBI:17191 (2)
CHEBI:17368 (2)
CHEBI:17724 (2)
CHEBI:18132 (2)
CHEBI:40992 (2)
CHEBI:43580 (2)
CHEBI:81555 (2)
CHEBI:10072 (1)
CHEBI:10101 (1)
CHEBI:10111 (1)
CHEBI:113543 (1)
CHEBI:1148 (1)
CHEBI:11814 (1)
CHEBI:12936 (1)
CHEBI:12962 (1)
CHEBI:133083 (1)

Metabolite Name

Choline (2)
Creatine (2)
Guanosine (2)
Hypoxanthine (2)
L-Arginine (2)
L-Histidine (2)
L-Isoleucine (2)
L-Valine (2)
N-Acetyl-L-alanine (2)
Phosphocholine (2)
Pyridoxine (2)
Uridine (2)
Xanthine (2)
()-Octanoylcarnitine (1)
(-)-11-Hydroxy-9,15,16-trioxooctadecanoic acid (1)
(3S,5R,6R,7E)-3,5,6-Trihydroxy-7-megastigmen-9-one (1)
(4R)-4-Hydroxy-L-glutamic acid (1)
(9Z,12Z)-(8R)-8-Hydroperoxyoctadeca-9,12-dienoic acid (HPODE) (1)
(E)-3-methylglutaconic acid (1)
(R)-(+)-2-Pyrrolidone-5-carboxylic acid (1)
(R)-3-Hydroxybutyric acid (1)
(S)-3-Hydroxybutyric acid (1)
1,2-Benzisothiazol-3(2H)-one (1)
1,3-Diaminopropane (1)
1-Ipomeanol (1)
1-Linoleoylglycerophosphocholine (1)
1-Methyl-L-histidine (1)
1-Methylhistamine (1)
1-Methylnicotinamide (1)
1-Naphthaleneacetic acid sodium salt (1)

Study type

Transcription profiling by array (7)
RNA-seq of coding RNA (3)
Comparative genomic hybridization by array (2)
ChIP-seq (2)
ChIP-chip by tiling array (1)
Cell line - High-throughput sequencing (1)
RNA-seq of total RNA (1)

Release Date

2025 (7)
2016 (6)
2012 (5)
2018 (5)
2022 (4)
2020 (4)
2013 (4)
2015 (3)
2011 (3)
2010 (3)
2024 (3)
2014 (3)
2017 (2)
2007 (1)
2023 (1)
2008 (1)

Lab affiliation

Associate Professor; Director of the Molecular and Applied Sciences Laboratory and Applied Physiology Laboratory (1)
Discovery Proteomics, Genentech (1)

Previous page
1 / 16
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 16
Next page

Sort by:

Relevance

Page size

Transcription profiling of yeast treated with rapamycin in a 7-part time series

This experiment was a 7-part time series (or, 2x7 factorial design) examining the effect of rapamycin on gene expression in Saccharomyces cerevisiae. Treated and untreated cultures were compared at 0, 20, 40, 60, 120, 240, and 360 minutes. In the paper, expression ratios (mRNA) at each time point ...

ORGANISM(S): Saccharomyces cerevisiae

2010-02-05 | E-TABM-639 | biostudies-arrayexpress

Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.

Not available

S-EPMC4872317 | biostudies-literature

A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease

Addona TA, Shi X, Keshishian H, Mani DR, Burgess M, Gillette MA, Clauser KR, Shen D, Lewis GD, Farrell LA, Fifer MA, Sabatine MS, Gerszten RE, Carr SA. Nat Biotechnol. 2011, 29(7):635-43. doi: 10.1038/nbt.1899. PMCID:PMC3366591. Discovery, AIMS, and MRM datasets Discovery_Tranche_hash: b/quYtp/Q8fY...

2013-12-19 | MSV000078513 | MassIVE

Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.

Not available

S-EPMC5891128 | biostudies-literature

Multiomic profiling of iron-deficient infant monkeys reveals alterations in neurologically important biochemicals in serum and cerebrospinal fluid before the onset of anemia

The effects of iron deficiency (ID) during infancy extend beyond the hematologic compartment and include short- and long-term adverse effects on many tissues including the brain. However, sensitive biomarkers of iron-dependent brain health are lacking in humans. To determine whether serum and cer...

2022-07-12 | MTBLS3388 | MetaboLights

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

Not available

S-EPMC4383838 | biostudies-literature

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

Not available

S-EPMC3675695 | biostudies-literature

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.

Not available

S-EPMC5791828 | biostudies-literature

Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Not available